- Home
- GYRE vs ECC Comparison
GYRE vs ECC Comparison
Compare GYRE & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- ECC
- Stock Information
- Founded
- GYRE 2002
- ECC N/A
- Country
- GYRE United States
- ECC United States
- Employees
- GYRE N/A
- ECC N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- ECC
- Sector
- GYRE Health Care
- ECC
- Exchange
- GYRE Nasdaq
- ECC NYSE
- Market Cap
- GYRE 1.1B
- ECC 966.1M
- IPO Year
- GYRE N/A
- ECC N/A
- Fundamental
- Price
- GYRE $12.02
- ECC $8.82
- Analyst Decision
- GYRE
- ECC Buy
- Analyst Count
- GYRE 0
- ECC 2
- Target Price
- GYRE N/A
- ECC $11.00
- AVG Volume (30 Days)
- GYRE 91.0K
- ECC 679.0K
- Earning Date
- GYRE 03-25-2025
- ECC 02-22-2024
- Dividend Yield
- GYRE N/A
- ECC 19.16%
- EPS Growth
- GYRE N/A
- ECC 369.44
- EPS
- GYRE N/A
- ECC 1.69
- Revenue
- GYRE $105,033,000.00
- ECC $122,654,279.00
- Revenue This Year
- GYRE $25.32
- ECC $36.58
- Revenue Next Year
- GYRE $12.95
- ECC $12.88
- P/E Ratio
- GYRE N/A
- ECC $5.93
- Revenue Growth
- GYRE N/A
- ECC 96.41
- 52 Week Low
- GYRE $8.26
- ECC $8.60
- 52 Week High
- GYRE $26.37
- ECC $11.79
- Technical
- Relative Strength Index (RSI)
- GYRE 54.44
- ECC 47.50
- Support Level
- GYRE $11.18
- ECC $8.69
- Resistance Level
- GYRE $11.85
- ECC $8.84
- Average True Range (ATR)
- GYRE 0.52
- ECC 0.07
- MACD
- GYRE 0.14
- ECC 0.01
- Stochastic Oscillator
- GYRE 83.91
- ECC 74.91
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About ECC EAGLE POINT CREDIT CO LLC
Eagle Point Credit Co Inc is an externally managed, non-diversified closed-end management investment company.